AI Reconstructs Drug Discovery The Transformation from Theoretical Breakthrough to Clinical Value [July 9th AI Half-Month Talk] Grand Launch
AI Reconstructs Drug Discovery: The Transformation from Theoretical Breakthrough to Clinical Value | [July 9th AI Half-Month Talk] Grand Launch
Highlight
01 Paradigm Shift in AI-Driven End-to-End Drug Discovery: From "Tool Empowerment" to "System Reconstruction"
02 Hardcore Closed Loop of "Virtual → Real": The "Triathlon" of Data, Algorithm, and Validation
03 Roundtable Debate:
Is AI More Prone to Achieving "me-better" Optimization? Or Can It Spur "first-in-class" or Even "first-in-human" Original Innovation?
AI Half-Month Talk [Issue 9]
With the rapid development of Artificial Intelligence (AI) technology, its application in drug research and development is gradually moving from concept to practice. AI not only accelerates early target identification and high-throughput virtual screening but also demonstrates great potential in structure prediction, candidate drug optimization, and other links. However, how to translate these cutting-edge technologies into practical outcomes with clinical value remains one of the major challenges facing the industry.
Against this backdrop, on July 9, 2025 (Wednesday) at 20:00, the 09th issue of "AI Half-Month Talk" invites Professor Zhao Yu from the Western Research Institute of Computing Technology, Deputy Director of the Turing-Darwin Laboratory and Co-founder of Zheyuan Technology, Zhou Debiao, General Manager of Oracle Life Sciences North Asia, Zhou Jielong, Founder and CEO of Stonewise, Dr. Lin Jian, Chief Commercial Officer of Drug Intelligence, and other distinguished guests to jointly discuss the latest progress and future trends of AI in the entire process of drug discovery. Colleagues from all walks of life are welcome to make an appointment to watch.
Live Broadcast Introduction
1、Live Broadcast Time
July 9, 2025 (Wednesday) at 20:00
2、Live Broadcast Guests
Zhao Yu | Professor at the Western Research Institute of Computing Technology, Deputy Director of the Turing-Darwin Laboratory, Co-founder of Zheyuan Technology
Zhou Debiao | General Manager of Oracle Life Sciences North Asia
Lin Jian | Chief Commercial Officer of Drug Intelligence
Zhou Jielong | Founder and CEO of Stonewise
Host:
Zhang Rui | Digital Transformation Expert in the Pharmaceutical Industry, Host of "AI Half-Month Talk" Column by Weijieyao
Guest Profiles
Zhao Yu
Professor at the Western Research Institute of Computing Technology
Deputy Director of the Turing-Darwin Laboratory
Co-founder of Zheyuan Technology
Ph.D., Professor at the Western Research Institute of Computing Technology, Deputy Director of the Turing-Darwin Laboratory, Co-founder of Zheyuan Technology, and Deputy Director of the Artificial Intelligence Big Data Branch of the China Biomedical Industry Chain Innovation and Transformation Alliance. He is one of the initiators and advocates of computational medicine and the convener of the "Computational Medicine Salon". He has long been deeply involved in the information technology industry and has nearly 20 years of experience in management and operation. Computational medicine is committed to developing quantitative scientific methods, using applied mathematics, engineering, and computational science, combined with biomedical knowledge, to intelligently understand the mechanisms of human diseases and construct digital simulations of life functions.
At present, two AI tool platforms have been built – a new target and new mechanism (MOA) presentation platform and a virtual clinical trial platform, targeting six application scenarios: new targets, new mechanisms of action, new biomarkers, designing clinical trial protocols, predicting clinical trial results, and expanding new indications. In cooperation with the clinical side, a series of "human-relevant" verification results have been produced! He is committed to innovating a new paradigm of drug research and development with a new technical system of computational medicine.
Zhou Debiao
General Manager of Oracle Life Sciences North Asia
General Manager of Oracle Life Sciences North Asia, Vice President of the Medical-Engineering Integration Branch of the China International Association for the Promotion of Science and Technology, and author of "Close Encounter with Artificial Intelligence" (Publishing House of Electronics Industry). He has more than 20 years of working experience in consulting companies and research and development institutions. He has rich practical experience in technological innovation and application of big data and artificial intelligence in the pharmaceutical industry.
Mr. Zhou Debiao is currently the General Manager of Oracle Life Sciences North Asia. He previously served as the Life Sciences Industry Director of Amazon AWS and the Chief Operating Officer of IBM Watson Health Division. He has rich practical experience in the application of digital technology in the medical and pharmaceutical fields and has guided the implementation of many industry-leading solutions including digital healthcare. While working daily, Mr. Zhou Debiao served as a faculty member at Waseda University from 2008 to 2011 and currently teaches the course "Artificial Intelligence and Its Applications" at the University of Chinese Academy of Sciences and Sichuan University. Mr. Zhou Debiao has individual patent certifications and has published academic papers in foreign professional journals.
Lin JianChief
Commercial Officer of Drug Intelligence
With more than 15 years of experience in the pharmaceutical industry, before joining Drug Intelligence, he served as the head of business cooperation at Alphamab and Yaotang Biotech, and has worked at foreign pharmaceutical companies such as Eisai, Boehringer Ingelheim, Johnson & Johnson, and Novartis. He has accumulated rich experience in business development, strategic alliance management, marketing and sales, product management, and investment. He has participated in and led the completion of more than 30 domestic and foreign licensing transactions, strategic cooperation, equity investment and other projects, with a total transaction amount exceeding 1.5 billion US dollars. He holds a bachelor's degree in biotechnology from Shandong University, a master's degree in biomedicine from the Chinese Academy of Sciences, an MBA from CEIBS, and is currently studying for a doctorate in medical and health management at the University of Montpellier, France.
Zhou Jielong
Founder and CEO of Stonewise
Master's degree in Artificial Intelligence from Beijing Institute of Technology; former Director Architect of Baidu. During his tenure at Baidu, he led the team to reconstruct Baidu's search engine with machine learning, making solid and innovative contributions to the systematicness, interpretability, and stability of machine learning, continuously improving the experience of long-tail queries and enhancing the efficiency of search research and development. In 2013, he successfully applied deep learning to search globally for the first time.
In recent years, he has continued to explore the field of AI + medicine. Based on the understanding that early drug discovery is essentially "exploration of a specific chemical space" (the appearance of search, the core of recommendation) and the concept of data-driven foundation models, he has introduced data governance, deep learning, generative AI, etc. into the early stage of drug research and development, and founded Stonewise.
Zhang Rui
Digital Transformation Expert in the Medical Industry
Host of "AI Half-Month Talk" Column by Weijieyao
Bachelor's degree in Biotechnology from Shanghai Jiao Tong University, Master's degree in Management from Antai College of Economics and Management, Shanghai Jiao Tong University.
With 15 years of working experience in foreign pharmaceutical companies, including product management, front-line sales, and personnel management; more than 10 years of experience in the marketing department. She has rich experience in market strategy, new product launch, and product life cycle management. She has successively worked in companies such as Eli Lilly, Xian Janssen, AstraZeneca, GSK, Merck, and Boehringer Ingelheim. She is familiar with therapeutic areas such as respiratory, cardiovascular, central nervous system, diabetes, oncology, women's health, and vaccines. She has in-depth insights and practical experience in new product launches, product life cycle management, and digital marketing.
Introduction to the "AI Half-Month Talk" Column
Artificial Intelligence (AI) technology is reshaping the medical and health field at an unprecedented speed. From disease diagnosis to personalized treatment, from drug research and development to health management, the application potential of AI is unlimited, but it is also accompanied by challenges such as data privacy protection, ethical disputes, and technical implementation difficulties. In order to let more people understand the actual value of AI in medical care and promote the attention and thinking of people inside and outside the industry on the development of AI medical care, "AI Half-Month Talk – Seeing the Power of Medical Intelligence Change" came into being.
As the first domestic in-depth dialogue live broadcast column focusing on the entire AI + medical industry chain, "AI Half-Month Talk" by E-Drug Manager · Weijieyao takes "prospectiveness, professionalism, and constructiveness" as its core concept. Each issue focuses on a vertical theme and invites top industry experts and practitioners to conduct in-depth discussions from multiple dimensions such as technological breakthroughs, clinical applications, industrial development, and policy supervision. Through four sections: Frontier Express, In-depth Focus, Case Disassembly, and Future Vision, the column is committed to building a "weathervane-style" dialogue platform in the medical technology field to help the industry witness the transformative power of AI empowering medical care.
• Previous Article: Stonewise Appears at AIBC2025, Focusing on Two Major Challenges of Molecular Generation Model Data and Evaluation
• Next Article: Stonewise Invites You to Participate in the 4th BIONNOVA Western Innovation Forum
